A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors

DOI: 10.1158/1535-7163.MCT-17-1204 Published December 2018

Online Impact

Volume 17, Issue 12, pp. 2702-2709

DOI

PubMed

Published By

Print ISSN

Online ISSN

History

¹Center for Regeneration Medicine, University of California, San Francisco, California.
²Diabetes Center, University of California, San Francisco, California.
³Department of Medicine, University of California, San Francisco, California.
⁴Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.
⁵Department of Cellular Molecular Pharmacology, University of California, San Francisco, California.
⁶Department of Pathology, University of California, San Francisco, California.
⁷Helen Diller Family HDF Comprehensive Cancer Center, University of California, San Francisco, California.
⁸Department of Surgery, University of California, San Francisco, California.

↵*Corresponding Authors:
Eric K. Nakakura, University of California, 1600 Divisadero Street, A-724, San Francisco, CA 94143-1932. Phone: 415-353-9294; Fax: 415-353-9695; E-mail: eric.nakakura{at}ucsf.edu; Chester E. Chamberlain, chester.chamberlain{at}ucsf.edu